Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company at the forefront of cancer immunotherapy. With a dedicated focus on developing investigational allogeneic chimeric antigen receptor T cell (AlloCAR T™) products, they aim to revolutionize cancer treatment. Led by a world-class management team with extensive experience in cell therapy, Allogene combines discovery, translational research, development, and cell manufacturing under one roof. Their goal is to create a pipeline of off-the-shelf CAR T cell candidates, providing readily available cell therapy to more patients with greater speed and reliability. Allogene's innovative approach utilizes gene editing to enhance the efficacy of their CAR T products. While these products are still in the investigational stage and not yet approved by the FDA, they hold great promise as a potentially transformative approach to cancer immunotherapy. With three locations, five clinical candidates, and thirteen preclinical targets, Allogene is committed to leading the next revolution in cancer treatment.